Vijaya’s Guwahati target has over Rs 25 crore revenue

Vijaya Diagnostic Centre Limited said on November 4, 2026, that Arya Wellness, its proposed Guwahati acquisition, has revenue above Rs 25 crore and pre-Ind AS EBITDA margin above 20%, making it an established business-to-consumer diagnostics platform rather than a greenfield Northeast entry. Management called the revenue base mature-state and said the transaction could take a couple of months to complete.

What financial profile does Arya Wellness bring?

Arya Wellness has revenue of more than Rs 25 crore and earnings before interest, tax, depreciation and amortisation, or EBITDA, of more than 20% on a pre-Indian Accounting Standards, or pre-Ind AS, basis, according to Vijaya management. The target is fully focused on business-to-consumer, or B2C, diagnostics and provides high-end pathology and radiology services.

An analyst described Arya Wellness’s current margin as 21%-22%, but Vijaya’s management stated only that it was above 20% on a pre-Ind AS basis. Vijaya did not disclose the target’s purchase consideration, net profit, test volumes, number of centres or post-acquisition EBITDA target during the November 4 call. The available disclosure therefore establishes an existing revenue and margin profile, but not a detailed valuation or earnings forecast.

The stated service mix provides context for the Rs 25 crore-plus revenue base. Management said Arya Wellness performs substantial histopathology work in pathology and conducts interventional radiology using computed tomography, or CT, and ultrasound machines. Vijaya also cited the target’s existing team and its proximity to hospitals, including a government medical college and hospital, as attributes of the proposed asset.

Why does Vijaya consider the Guwahati target mature?

Vijaya considers Arya Wellness mature because it already generates more than Rs 25 crore of revenue and more than 20% pre-Ind AS EBITDA. Management said a hub with revenue close to Rs 25 crore is not a small operation and explicitly described the target as having mature-state revenue. That is management’s assessment of the current asset, not guidance for future growth.

The distinction is relevant when compared with more recently developed clusters. In Pune, Vijaya said revenue per centre was broadly stable at Rs 2.5 crore because the existing three hubs and more than 10 spokes were at a steadier growth stage. Growth there was predominantly coming from network additions, including the Kalyani Nagar and Ambegaon hubs, which had been operating for about one to 1.5 years and were still ramping up.

Vijaya also contrasted the target’s existing economics with the performance of newly opened facilities. Management said its Bengaluru JP Nagar flagship was the only centre opened in the relevant quarter, following the Gachibowli hub and spokes opened in the first quarter. It reported no material EBITDA drag from those openings and said 10 hubs added in the prior year had also not caused significant margin pressure because they ramped as expected or faster.

How could Vijaya develop the Guwahati cluster?

Vijaya said Arya Wellness could become a platform for further expansion in Guwahati. Its stated model is to add spokes around a mature hub, then seek operational efficiency and margin improvement at the cluster level. Management said it would share more data on the strategy and potential for the region after completing the transaction.

That approach matches Vijaya’s broader plan to build dense regional networks rather than expand rapidly across India. Management identified Bengal, Karnataka and the Northeast as geographies where it intends to add hubs followed by spokes. However, it cautioned that the 10 hubs added in the prior year should not be treated as a fixed annual expansion rate, because it gives expansion guidance for the next two to three quarters.

The eventual Guwahati service mix will depend on the number and type of sites Vijaya adds. Management said pathology and radiology revenue have remained around 67% and 37%, respectively, with movement of only 1%-2% depending on the balance of hubs and spokes. Hubs have a higher radiology component, while spokes provide pathology and basic radiology, but Vijaya did not disclose a Guwahati rollout configuration.

What does Vijaya still need to disclose about the deal?

Vijaya said the proposed transaction could take a couple of months to complete and that more details should be available by the next quarter. It did not disclose the final closing date, transaction value, funding structure, ownership stake, closing conditions or accounting treatment. The Rs 25 crore-plus revenue and above-20% EBITDA figures therefore describe the target before consolidation into Vijaya’s reported financial statements.

Vijaya also has not disclosed the number of future Guwahati spokes, capital expenditure, lease commitments, revenue per centre or a schedule for cluster profitability. Its group-wide property strategy remains predominantly asset-light. Management said that, if it added 10 future centres, nine would generally be leased and one might be owned in a prime metro location, but it gave no equivalent property plan for Guwahati.

The company did not quantify the contribution of histopathology, CT-based interventional radiology or ultrasound-based procedures to Arya Wellness’s revenue. Nor did it provide pathology-radiology revenue shares, capacity data, or plans for the existing team following completion. These omissions limit a granular comparison with Vijaya’s operations even though management has described the target as a B2C and high-end diagnostics business.

How does the acquisition fit Vijaya’s expansion model?

Vijaya said its model is to identify an addressable market, establish hubs and add spokes to build local density. In Hyderabad, management said the centre count increased from 94 two years earlier to 100, while existing centres drove higher throughput. It also said it had commissioned one hub and four spokes in Hyderabad by the first half and expected to commission at least three to four more spokes during the year.

Management’s capacity decisions are tied to patient demand rather than a fixed equipment formula. It said a second magnetic resonance imaging, or MRI, machine may be considered when daily scans increase from an initial comfortable 15-16 to about 25 and patient waits exceed one to two hours. Vijaya did not provide Arya Wellness’s scan volumes, MRI equipment, wait times or demand indicators, so this approach cannot yet be applied directly to Guwahati.

Vijaya also said the share of preventive and wellness revenue has been around 14%-15% and may not change materially over the next couple of years, although management said that segment grew by close to 27% in the second quarter. The Guwahati target’s disclosed profile instead centres on B2C diagnostics, histopathology and interventional radiology, with no separate preventive-care revenue figure supplied.

Conclusion

Arya Wellness offers Vijaya a proposed Northeast entry with more than Rs 25 crore in revenue, pre-Ind AS EBITDA above 20% and an existing B2C diagnostics model. Management’s mature-asset assessment is grounded in the target’s stated scale, established margin and higher-end pathology and radiology capabilities, distinguishing it from a newly opened hub that first needs to develop patient throughput.

The next event to watch is the transaction update Vijaya said it expects to provide by the next quarter, after the couple of months it estimated for completion. Management has indicated it will then disclose more on regional strategy and growth potential; unresolved matters include transaction terms, the spoke rollout, capital needs and the margin trajectory of the Guwahati cluster.